Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

dechloroethylifosfamide

Known as: 2-DClIF, 2-dechloroethylifosfamide, 2-amino-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazophosphorine-2-o-xide 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Ifosfamide
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OG-FET: An In-Situ ${O}$ xide, ${G}$ aN Interlayer-Based Vertical Trench MOSFET
In this letter, a novel device design to achieve both low ON-resistance and enhancement mode operation in a vertical GaN FET is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
WILDLIFE CONTRACEPTION: TARGETING THE OOCYTE
The USDA’s National Wildlife Research Center (NWRC) has successfully researched and developed a number of chemical and… Expand
Highly Cited
2004
Highly Cited
2004
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy
The initial metabolism of the oxazaphosphorine cytostatic ifosfamide (IF) consists of two different pathways: ring oxidation at… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2004
Highly Cited
2004
Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity
Repeated administration of agents (e.g., cancer chemotherapy) that can cause drug-induced nephrotoxicity may lead to acute or… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2000
Highly Cited
2000
Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.
Nephrotoxicity is a limiting factor in the use of ifosfamide in children. Despite the co-administration of uroprotective agents… Expand
1997
1997
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy
Abstract The oxazaphosphorine antineoplastic ifosfamide (IF) is metabolized by two different initial pathways: ring oxidation… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
1996
1996
Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide.
A combination of high-resolution nuclear magnetic resonance (NMR) and high-performance liquid chromatography (HPLC)-NMR… Expand
1996
1996
e Characteristics of Polysilicon xide Grown in Pure N2O
This work reports on the characteristics of polysil- icon oxide grown in pure N20 (NzO-grown polyoxide). The obtained polyoxide… Expand
1992
1992
A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
[31P] nuclear magnetic resonance spectroscopy was used to analyze body fluids from patients treated with ifosfamide (IF). This… Expand
1983
1983
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Isophosphoramide mustard was synthesized and was found to demonstrate activity essentially comparable to cyclophosphamide and… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE